NCT07138352View on ClinicalTrials.gov

Bioavailability Study of XS003 (Nilotinib)

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 3, 2024

Primary Completion Date

January 8, 2025

Study Completion Date

January 8, 2025

Conditions
Cancer
Interventions
DRUG

XS003 under fed and fasted condition

XS003 under fed and fasted condition

Trial Locations (1)

65802

QPS Missouri, Springfield

All Listed Sponsors
lead

Xspray Pharma AB

INDUSTRY

NCT07138352 - Bioavailability Study of XS003 (Nilotinib) | Biotech Hunter | Biotech Hunter